A case report of drug-induced ischemic colitis accompanied by ulcerative colitis

2021 ◽  
Vol 44 (2) ◽  
pp. 137-138
Author(s):  
Guanyu Zhou ◽  
Fei Xiong ◽  
Xudan Yang ◽  
Pu Wang
Keyword(s):  
Ulcerative Colitis ◽  
Case Report ◽  
Ischemic Colitis ◽  
Drug Induced

scholarly journals DRUG-INDUCED BILATERAL NEPHROLITHIASIS IN AN ULCERATIVE COLITIS PATIENT: A CASE REPORT

2019 ◽  
Vol 110 (1) ◽  
pp. 41-46 ◽  
Author(s):  
Kohei Ogawa ◽  
Kazushige Sakaguchi ◽  
Suguru Oka ◽  
Shoichi Nagamoto ◽  
Kazuhiro Kurosawa ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Case Report ◽  
Ulcerative Colitis Patient ◽  
Colitis Patient ◽  
Drug Induced

scholarly journals Ischemic colitis induced by indigo naturalis in a patient with ulcerative colitis: a case report

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Byungha Cho ◽  
Soon Man Yoon ◽  
Seung-Myoung Son ◽  
Hyoung Woo Kim ◽  
Ki Bae Kim ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Case Report ◽  
Ischemic Colitis ◽  
Indigo Naturalis

scholarly journals Eosinophilic Pneumonia in a Patient With Ulcerative Colitis Treated With Mesalazine: a Case Report

2021 ◽  
Author(s):  
Yizhou Hu ◽  
Yan Chen
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Case Report ◽  
Rare Complication ◽  
Pulmonary Complications ◽  
Eosinophilic Pneumonia ◽  
Drug Induced ◽  
Case Presentation ◽  
Causative Drug ◽  
Inflammatory Bowel

Abstract Background: Mesalazine, also known as mesalamine or 5-ASA, is considered a safe drug and thus widely prescribed for Inflammatory bowel disease (IBD) patients. Mesalazine was previously recognized as a drug that can rarely cause pneumonia because lacking a sulfa component. Nevertheless, although still a rare complication, more and more cases have been reported nowadays. Case presentation: We describe the case of eosinophilic pneumonia (EP) in a 39-year-old woman with ulcerative colitis during treatment with mesalazine. We discontinued mesalazine after drug-induced EP was identified, and she made a prompt recovery.Conclusions: The diagnosis of EP is readily missed due to the rarity and the pulmonary complications of IBD. Since the treatment of pulmonary complications of IBD and EP varies, it is crucial to differentiate them. A prompt recovery can be expected in patients with EP after discontinuing the causative drug.

scholarly journals Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report

2021 ◽  
Vol 22 (12) ◽  
pp. 6480
Author(s):  
Céline K. Stäuble ◽  
Markus L. Lampert ◽  
Thorsten Mikoteit ◽  
Martin Hatzinger ◽  
Kurt E. Hersberger ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Case Report ◽  
Adverse Drug Reactions ◽  
Active Metabolite ◽  
Hepatic Metabolism ◽  
Cytochrome P450 3A4 ◽  
Drug Reactions ◽  
Drug Induced ◽  
Potential Impact ◽  
Intermediate Metabolizer

We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient’s pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine.

scholarly journals Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature

2021 ◽  
Vol 8 (1) ◽  
pp. e000587
Author(s):  
Giacomo Caio ◽  
Lisa Lungaro ◽  
Fabio Caputo ◽  
Maria Muccinelli ◽  
Maria Caterina Marcello ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Case Report ◽  
Inflammatory Bowel Diseases ◽  
Drug Toxicity ◽  
Active Ulcerative Colitis ◽  
Extraintestinal Manifestations ◽  
Review Of The Literature ◽  
Extraintestinal Manifestation ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Inflammatory bowel diseases such as ulcerative colitis (UC) may be complicated by several extraintestinal manifestations. These involve joints, skin, eyes and less commonly lungs and heart. Myocarditis may result from the toxic effect of drugs (ie, mesalazine) commonly used for the treatment of UC or due to infections (eg, Coxsackieviruses, enteroviruses, adenovirus). Here, we report a case of a 26-year old man affected by UC and complicated by two episodes of myocarditis. Both episodes occurred during two severe exacerbations of UC. However, in both cases the aetiology of myocarditis remains uncertain being ascribable to extraintestinal manifestation, drug toxicity or both.

Sign in / Sign up

Export Citation Format

Share Document